RVPH Insider Trading Activity and SEC Form 4 Filings
RVPH insider trading summary
No open-market insider purchases or sales of Reviva Pharmaceuticals Holdings, Inc. (RVPH) have been reported on SEC Form 4 in the past 12 months.
Latest RVPH insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 18, 2022 | Purav Patel | Director | Buy | $14K (3,000 @ $4.69) |
| Sep 30, 2022 | Prabhu Narayan | Chief Financial Officer | Buy | $83K (50,000 @ $1.66) |
| Jun 30, 2022 | Prabhu Narayan | Chief Financial Officer | Buy | $61K (50,000 @ $1.21) |
| Jun 1, 2021 | Vedanta Partners, LLC | 10% Owner | Buy | $3.5M (931,000 @ $3.75) |
| Jun 1, 2021 | Parag Saxena | Director | Buy | $1.5M (399,000 @ $3.75) |
| Jun 1, 2021 | Beta Operators Fund, L.P. | 10% Owner | Buy | $1.5M (399,000 @ $3.75) |
| Jun 1, 2021 | Beta Operators Fund, L.P. | 10% Owner | Buy | $3.5M (931,000 @ $3.75) |
| Jun 1, 2021 | Parag Saxena | Director | Buy | $3.5M (931,000 @ $3.75) |
| Jun 1, 2021 | Vedanta Associates, L.P. | 10% Owner | Buy | $1.5M (399,000 @ $3.75) |
| Jun 1, 2021 | Vedanta Associates-R, LP | 10% Owner | Buy | $1.5M (399,000 @ $3.75) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.